

Hypercholesterolaemia - Pipeline Insight, 2021

<https://marketpublishers.com/r/H2F849ADA97CEN.html>

Date: June 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H2F849ADA97CEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Hypercholesterolaemia - Pipeline Insight, 2021," report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hypercholesterolaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hypercholesterolaemia Understanding

Hypercholesterolaemia: Overview

Cholesterol is a component (a lipid or fat) that circulates in the bloodstream which the body uses to construct cells and produce certain substances that it needs. In this respect, its presence is both good and necessary. However, hypercholesterolaemia, or an excessive level or amount of cholesterol in the blood, can be harmful because it causes atheromatous plaques to deposit in the arteries (atherosclerosis). Therefore, it predisposes the development of cardiovascular diseases such as heart attacks, strokes or an insufficient blood supply to the limbs.

The need for treatment to reduce cholesterol levels must be individualised to each person and largely depends on the risk of suffering a cardiovascular event. There are

several strategies to reduce cholesterol with medicines. For instance, there are drugs that decrease cholesterol production in the liver or which enable the liver to capture or “clean” more cholesterol from the blood. Statins are the treatment of choice and best-known drug therapy against hypercholesterolaemia. Ezetimibe acts by reducing cholesterol absorption in the intestine. Resins act in the intestine by promoting the elimination of bile which has a very high cholesterol content.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hypercholesterolaemia R&D. The therapies under development are focused on novel approaches for Hypercholesterolaemia.

Hypercholesterolaemia Emerging Drugs Chapters

This segment of the Hypercholesterolaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypercholesterolaemia Emerging Drugs

IBI306: Innovent Biologics

Tafolecimab (IBI306) is a recombinant fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) developed by Innovent for the treatment of hypercholesterolemia. PCSK9 binds the LDL-R/LDL-C complex and prevents LDL-R dissociation, make it to degrade with LDL-C and thus cannot circulate back to the hepatic cell surface. As the amount of LDL-R expression on the cell surface decreases, the level of LDL-C in the blood will accumulate and increase. Tafolecimab targets PCSK9 and inhibits its binding to LDL-R on the liver cell surface, maintaining the expression of LDL-R on the hepatocyte surface, thereby reducing LDL-C levels.

It is currently in Phase III stage of development for Hypercholesterolaemia and is being developed by Innovent Biologics.

AK-102: Akeso Biopharma

Ebronicimab (AK102) acts as inhibitors of PCSK9 protein. Ebronicimab (AK102) is being developed for the treatment of acquired and inherited hyperlipidemias, including HoFH, HeFH, and hypercholesterolemias patients with atherosclerotic cardiovascular disease.

It is currently in Phase II stage of development for Hypercholesterolaemia and is being developed by Akeso Biopharma.

Further product details are provided in the report..

Hypercholesterolaemia: Therapeutic Assessment

This segment of the report provides insights about the different Hypercholesterolaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Hypercholesterolaemia

There are approx. 20+ key companies which are developing the Hypercholesterolaemia. The companies which have their Hypercholesterolaemia drug candidates in the most advanced stage, i.e. Phase III include, Innovent Biologics.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hypercholesterolaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypercholesterolaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hypercholesterolaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypercholesterolaemia drugs.

Hypercholesterolaemia Report Insights

Hypercholesterolaemia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hypercholesterolaemia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Hypercholesterolaemia drugs?

How many Hypercholesterolaemia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Hypercholesterolaemia?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hypercholesterolaemia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hypercholesterolaemia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Akeso Biopharma

LIB Therapeutics

Innovent Biologics

Jiangsu HengRui Medicine

AstraZeneca

Vaxxinity

Key Products

AK102

IBI306

Lerodalcibep

SHR-1209

AZD8233

Research programme: PCSK 9 inhibitor vaccine

Contents

Introduction

Executive Summary

Hypercholesterolaemia: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Hypercholesterolaemia– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Hypercholesterolaemia companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Hypercholesterolaemia Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

IBI306: Innovent Biologics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

AK102: Akeso Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Preclinical and Discovery Stage Products

Comparative Analysis

Research programme: PCSK 9 inhibitor vaccine: Vaxxinity

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Inactive Products

Comparative Analysis

Hypercholesterolaemia Key Companies

Hypercholesterolaemia Key Products

Hypercholesterolaemia- Unmet Needs

Hypercholesterolaemia- Market Drivers and Barriers

Hypercholesterolaemia- Future Perspectives and Conclusion

Hypercholesterolaemia Analyst Views

Hypercholesterolaemia Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Hypercholesterolaemia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Hypercholesterolaemia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hypercholesterolaemia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/H2F849ADA97CEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H2F849ADA97CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970